Vanguard Group
ALGS icon

Vanguard Group’s Aligos Therapeutics ALGS Stock Holding History

Vanguard Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.87M Buy
200,395
+28,706
+17% +$271K ﹤0.01% 3578
2025
Q3 		$1.68M Buy
171,689
+31,913
+23% +$292K ﹤0.01% 3629
2025
Q2 		$1.01M Sell
139,776
-973
-0.7% -$5.82K ﹤0.01% 3741
2025
Q1 		$1.16M Buy
140,749
+43,987
+45% +$964K ﹤0.01% 3668
2024
Q4 		$3.85M Buy
96,762
+32,948
+52% +$637K ﹤0.01% 3366
2024
Q3 		$553K Hold
63,814
– – ﹤0.01% 3949
2024
Q2 		$558K Buy
63,814
+23,291
+57% +$409K ﹤0.01% 3971
2024
Q1 		$993K Buy
40,523
+57
+0.1% +$1.14K ﹤0.01% 3815
2023
Q4 		$672K Buy
40,466
+41
+0.1% +$705 ﹤0.01% 3948
2023
Q3 		$755K Buy
40,425
+637
+2% +$14.1K ﹤0.01% 3929
2023
Q2 		$966K Sell
39,788
-879
-2% -$23.6K ﹤0.01% 3912
2023
Q1 		$889K Buy
40,667
+127
+0.3% +$4.85K ﹤0.01% 3955
2022
Q4 		$966K Sell
40,540
-3,060
-7% -$77.1K ﹤0.01% 3926
2022
Q3 		$1.2M Buy
43,600
+1,093
+3% +$36.3K ﹤0.01% 3944
2022
Q2 		$1.29M Sell
42,507
-8,884
-17% -$302K ﹤0.01% 4000
2022
Q1 		$2.76M Sell
51,391
-3,606
-7% -$289K ﹤0.01% 3818
2021
Q4 		$16.3M Buy
54,997
+3,988
+8% +$1.45M ﹤0.01% 2949
2021
Q3 		$19.8M Buy
51,009
+11,677
+30% +$4.62M ﹤0.01% 2869
2021
Q2 		$20M Buy
39,332
+14,742
+60% +$9.4M ﹤0.01% 2844
2021
Q1 		$14M Buy
24,590
+162
+0.7% +$108K ﹤0.01% 2970
2020
Q4 		$16.9M Buy
+24,428
New +$11.9M ﹤0.01% 2727

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group's ALGS Position: Q4 2025 in Review

Vanguard Group increased its Aligos Therapeutics (ALGS) stake by 17% in Q4 2025, buying an estimated $271K and bringing the position to 200,395 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3578.

Vanguard Group first reported a position in ALGS in Q4 2020 and has held it in 21 quarters since. The position peaked at $20M in Q2 2021. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

  • Vanguard Group held 200,395 shares of Aligos Therapeutics worth $1.87M as of Q4 2025.
  • Vanguard Group bought 28,706 Aligos Therapeutics shares in Q4 2025, an estimated $271K.
  • Aligos Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3578 holding.
  • Vanguard Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's Aligos Therapeutics position peaked at $20M in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.